Doubly-robust evaluation of high-dimensional surrogate markers

12/02/2020
by   Denis Agniel, et al.
0

When evaluating the effectiveness of a treatment, policy, or intervention, the desired measure of effectiveness may be expensive to collect, not routinely available, or may take a long time to occur. In these cases, it is sometimes possible to identify a surrogate outcome that can more easily/quickly/cheaply capture the effect of interest. Theory and methods for evaluating the strength of surrogate markers have been well studied in the context of a single surrogate marker measured in the course of a randomized clinical study. However, methods are lacking for quantifying the utility of surrogate markers when the dimension of the surrogate grows and/or when study data are observational. We propose an efficient nonparametric method for evaluating high-dimensional surrogate markers in studies where the treatment need not be randomized. Our approach draws on a connection between quantifying the utility of a surrogate marker and the most fundamental tools of causal inference – namely, methods for estimating the average treatment effect. We show that recently developed methods for incorporating machine learning methods into the estimation of average treatment effects can be used for evaluating surrogate markers. This allows us to derive limiting asymptotic distributions for key quantities, and we demonstrate their good performance in simulation.

READ FULL TEXT
research
09/17/2022

Towards Optimal Use of Surrogate Markers to Improve Power

Motivated by increasing pressure for decision makers to shorten the time...
research
12/23/2017

On the Individual Surrogate Paradox

When the primary outcome is difficult to collect, surrogate endpoint is ...
research
09/17/2022

Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect

The primary benefit of identifying a valid surrogate marker is the abili...
research
06/02/2021

Online Experimentation with Surrogate Metrics: Guidelines and a Case Study

A/B tests have been widely adopted across industries as the golden rule ...
research
04/27/2021

Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm

A surrogate endpoint S in a clinical trial is an outcome that may be mea...
research
03/27/2020

On the role of surrogates in the efficient estimation of treatment effects with limited outcome data

We study the problem of estimating treatment effects when the outcome of...

Please sign up or login with your details

Forgot password? Click here to reset